Pomegranate ellagitannins has 4 documented interactions in Magellan’s curated dataset, covering Blood pressure medications, Statins (cholesterol medications), Anticoagulants (blood thinners), NSAID pain relievers, Antidepressants (SSRIs and SNRIs). Each entry below gives the mechanism as the cited reference states it, the direction the risk runs, how serious that reference treats it, and what to actually do about it — which is, in every case, a conversation with the clinician or pharmacist who manages the prescription rather than a decision you make alone.
What it is. Pomegranate ellagitannin extract is a concentrated source of ellagitannins (such as punicalagins) and ellagic acid, the polyphenols responsible for much of the pomegranate's antioxidant activity. After ingestion, these compounds are hydrolyzed to ellagic acid and then metabolized by the gut microbiota into urolithins, chiefly urolithin A.
Where it sits on the evidence. Magellan grades the supplement itself as Moderate evidence. That grade is about whether it works, not about whether it is safe alongside your medication — the two questions are independent, and this page answers only the second.
Products this covers: Pomegranate Ellagitannin Extract.
How the risks cluster. The entries split across 3 different mechanisms — additive; drug levels; bleeding risk — and they are not managed the same way, so read each one rather than assuming a single rule covers all of them.
Safety and efficacy are separate questions, and this page only answers the first. For the second, the study Magellan’s coverage of Pomegranate ellagitannins rests on is:
“In 261 adults aged 50–75, daily pomegranate juice for 12 months kept visual memory performance stable while the placebo group declined.”
A strong result does not make a supplement safe alongside your prescription, and a documented interaction does not mean the supplement does not work. Magellan grades those two things separately, and neither grade moves for a commission.
Magellan’s Medication Safety Check runs entirely on your device — type the medicines you take and it flags every documented interaction in this dataset. Nothing you type is sent anywhere.
Open the Medication Safety Check →Pomegranate appears to lower blood pressure on its own; combined with antihypertensive drugs it may push blood pressure too low.
Medicines in this group include: Amlodipine (Norvasc), Diltiazem (Cardizem, Tiazac), Verapamil (Calan, Verelan), Nifedipine (Procardia, Adalat), Hydrochlorothiazide (Hctz, Microzide), Chlorthalidone (Thalitone), Indapamide (Lozol), Furosemide (Lasix) and 6 more.
Pomegranate juice/extract may slow how the liver breaks down certain statins, increasing statin levels and side-effect risk.
Medicines in this group include: Atorvastatin (Lipitor), Simvastatin (Zocor), Rosuvastatin (Crestor), Lovastatin (Mevacor, Altoprev), Pravastatin (Pravachol), Pitavastatin (Livalo), Fluvastatin (Lescol).
Pomegranate juice may slow the breakdown of warfarin, increasing its blood-thinning effect and bleeding risk; INR monitoring is advised.
Medicines in this group include: Warfarin (Coumadin, Jantoven), Apixaban (Eliquis), Rivaroxaban (Xarelto), Dabigatran (Pradaxa), Edoxaban (Savaysa), Heparin (Lovenox, Enoxaparin), Acenocoumarol (Sintrom).
Pomegranate may inhibit CYP2C9 and CYP2D6 enzymes, potentially raising blood levels of drugs metabolized by these pathways.
Medicines in this group include: Ibuprofen (Advil, Motrin), Naproxen (Aleve, Naprosyn), Meloxicam (Mobic), Celecoxib (Celebrex), Diclofenac (Voltaren, Cataflam), Indomethacin (Indocin), Sertraline (Zoloft), Fluoxetine (Prozac) and 9 more.
These are the warning signs that go with the medication classes on this page. They are general safety-netting, not a prediction that any supplement will cause them.
If something feels seriously wrong, do not wait for an appointment. Call 911 (US) or your local emergency number.
Severity describes the interaction as the cited reference frames it, not how a specific person will react. A “minor” entry in someone with kidney disease, on five other drugs, can matter more than a “major” one in someone on nothing else.
This is a curated set of interactions with citations — not an exhaustive pharmacology database. An interaction that is absent here has not been ruled out; it may simply not be documented in the references Magellan curates from. Supplements are also not batch-tested for identity or contamination the way prescription drugs are, so what is on the label is a claim rather than a guarantee. And most of these entries come from case reports and mechanistic work rather than randomized trials, which is exactly why the sensible response is a pharmacist review rather than either alarm or dismissal.
15 documented interactions across 14 supplements.
9 documented interactions across 9 supplements.
22 documented interactions across 17 supplements.
8 documented interactions · shares a drug class with Pomegranate ellagitannins.
4 documented interactions · shares a drug class with Pomegranate ellagitannins.
3 documented interactions · shares a drug class with Pomegranate ellagitannins.
3 documented interactions · shares a drug class with Pomegranate ellagitannins.
The mechanism and the research behind the compound itself.
A–Z of every supplement and drug class in this dataset, plus how to read an interaction.
What the research actually shows, graded independently of affiliate commissions.
Not without checking with the prescriber or pharmacist first. Magellan's dataset grades this as a moderate interaction: Pomegranate appears to lower blood pressure on its own; combined with antihypertensive drugs it may push blood pressure too low. (Source: Pomegranate: Health Benefits, Side Effects, Uses, Dose & Precautions.)
4 interactions are documented in Magellan's curated dataset: 3 moderate, 1 minor. They cover Blood pressure medications, Statins (cholesterol medications), Anticoagulants (blood thinners), NSAID pain relievers, Antidepressants (SSRIs and SNRIs). Absence from this list is not proof of safety — it means no interaction is documented in the references we curate from.